Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INFRADYNAMICS

Financiado

Overcoming the Barriers of Brain Cancer Treatment Targeted and Fully NIR Absorb...

Overcoming the Barriers of Brain Cancer Treatment Targeted and Fully NIR Absorbing Photodynamic Therapy Agents with Extremely Low Molecular Weights and Controlled Lipophilicity Cancer is the second leading cause of death worldwide, accounting for a total of 8.8 million deaths in 2015. Research efforts have resulted in significant increase in 5-year survival rates for some cancer types, however this is no... ver más

31/10/2025

METU

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

MIDDLE EAST TECHNICAL UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-10-18

ERC-2019-STG: ERC Starting Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

METU

1.50M€ | Lider

ESNELAT

289.40K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-127187OB-C22 ESTRATEGIAS AVANZADAS EN EL DISEÑO DE FOTOSENSIBILIZADORES B... 91K€ Cerrado

RTI2018-100709-B-C22 NUEVOS METALOFARMACOS DISEÑADOS PARA INCREMENTAR LA SELECTIV... 57K€ Cerrado

CTQ2010-20870-C03-02 NUEVAS ESTRATEGIAS PARA TERAPIA FOTODINAMICA DIRIGIDA. 3. SI... 44K€ Cerrado

CTQ2010-20870-C03-03 NUEVAS ESTATEGIAS PARA TERAPIA FOTODINAMICA DIRIGIDA. 2. BIO... 59K€ Cerrado

UNPV13-4E-1862 FOTÓLISIS LÁSER: equipo para el registro cinético y espectra... 130K€ Cerrado

CTQ2016-80844-R NANOMATERIALES DE CONVERSION ASCENDENTE PARA QUIMIOTERAPIA F... 85K€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2019-10-18
Fecha Fin: 2025-10-31

Líder del proyecto

MIDDLE EAST TECHNICAL UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is the second leading cause of death worldwide, accounting for a total of 8.8 million deaths in 2015. Research efforts have resulted in significant increase in 5-year survival rates for some cancer types, however this is not the case in brain cancer. Three fundamental issues are at the core of this reality: 1) High percentage of inoperable brain tumours; 2) Limited number of drugs that can pass through the blood-brain barrier and 3) Absence of effective targeted brain cancer therapies. Photodynamic therapy (PDT) has the potential to be a selective, effective and non-invasive alternative to current treatments, however to date it is only applicable to a small group of cancers. Realization of non-toxic, water-soluble and photostable PDT agents, with strong near infrared absorption for deep tissue penetration, that also realizes high singlet oxygen generation efficiency and effective targeting, is the key for widespread use of PDT for majority of cancers. For brain cancer specifically, low molecular weights (Mws) and controlled lipophilicity is needed as well. The ultimate aim of INFRADYNAMICS is to create and validate the first series of advanced PDT agents that meet all these requirements and to demonstrate that a significant impact on brain cancer survival rates could be achieved. First, a series of advanced fluorophores that combine the two contradicting entities – absorption in NIR region (>700 nm) and low Mws – will be realized using novel design approaches which also allow a synthetically-viable pathway to tune lipophilicity. Then, appropriate heavy atom modifications for sensitization will be pursued. Most importantly, these sensitizers will be decorated with known and novel handles towards specific targeting of glioblastoma cells to attain the final PDT agents. Photophysical properties will be investigated, and finally, in-vitro and in-vivo studies will be performed to determine the effectiveness of our agents on brain cancer treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores